Seattle Genetics, Takeda complete enrollment in phase 3 trial of ADCETRIS in frontline mature T-cell lymphoma

Seattle Genetics and Takeda Pharmaceutical Company have completed patient enrollment in the ECHELON-2 clinical trial, assessing ADCETRIS (Brentuximab Vedotin) in frontline mature T-cell lymphoma.
Read the full story: PBR - Clinical Trials News